Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management

被引：69

作者：

Sutic, Maja ^{[1
]}

Vukic, Ana ^{[1
]}

Baranasic, Jurica ^{[1
]}

Foersti, Asta ^{[2
,3
]}

Dzubur, Feda ^{[4
,5
]}

Samarzija, Miroslav ^{[4
,5
]}

Jakopovic, Marko ^{[4
,5
]}

Brcic, Luka ^{[6
]}

Knezevic, Jelena ^{[1
,7
]}

机构：

[1] Rudjer Boskovic Inst, Div Mol Med, Zagreb 10000, Croatia

[2] Hopp Childrens Canc Ctr KiTZ, D-69120 Heidelberg, Germany

[3] German Canc Res Ctr, Div Pediat Neurooncol, D-69120 Heidelberg, Germany

[4] German Canc Consortium DKTK, D-69120 Heidelberg, Germany

[5] Univ Zagreb, Univ Hosp Ctr Zagreb, Sch Med, Clin Dept Resp Dis Jordanovac, Zagreb 10000, Croatia

[6] Med Univ Graz, Diagnost & Res Inst Pathol, A-8010 Graz, Austria

[7] Univ Osijek, Faculties Dent Med & Hlth, Osijek 31000, Croatia

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 11期

关键词：

lung cancer; adenocarcinoma; squamous cell lung cancer; biomarker; diagnosis; prognosis; targeted therapy; immunotherapy; III BETA-TUBULIN; ENDOTHELIAL GROWTH-FACTOR; MOLECULAR TESTING GUIDELINE; PREVIOUSLY TREATED PATIENTS; RECEPTOR TYROSINE KINASES; TO-LYMPHOCYTE RATIO; SINGLE-ARM; PROTEIN EXPRESSION; EARLY-STAGE; OPEN-LABEL;

D O I：

10.3390/jpm11111102

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Lung cancer is the leading cause of cancer-related deaths worldwide. Despite growing efforts for its early detection by screening populations at risk, the majority of lung cancer patients are still diagnosed in an advanced stage. The management of lung cancer has dramatically improved in the last decade and is no longer based on the "one-fits-all " paradigm or the general histological classification of non-small cell versus small cell lung cancer. Emerging options of targeted therapies and immunotherapies have shifted the management of lung cancer to a more personalized treatment approach, significantly influencing the clinical course and outcome of the disease. Molecular biomarkers have emerged as valuable tools in the prognosis and prediction of therapy response. In this review, we discuss the relevant biomarkers used in the clinical management of lung tumors, from diagnosis to prognosis. We also discuss promising new biomarkers, focusing on non-small cell lung cancer as the most abundant type of lung cancer.

引用

页数：27

共 207 条

[1] An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer [J].

Ahmadzada, Tamkin ;

Kao, Steven ;

Reid, Glen ;

Boyer, Michael ;

Mahar, Annabelle ;

Cooper, Wendy A. .

JOURNAL OF CLINICAL MEDICINE, 2018, 7 (06)

[2] Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis [J].

Al-Saleh, K. ;

Quinton, C. ;

Ellis, P. M. .

CURRENT ONCOLOGY, 2012, 19 (01) :E9-E15

[3] Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell? [J].

Alexander, Mariam ;

Galeas, Jose ;

Cheng, Haiying .

JOURNAL OF THORACIC DISEASE, 2018, 10 :S3994-S3998

[4] Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries [J].

Allemani, Claudia ;

Matsuda, Tomohiro ;

Di Carlo, Veronica ;

Harewood, Rhea ;

Matz, Melissa ;

Niksic, Maja ;

Bonaventure, Audrey ;

Valkov, Mikhail ;

Johnson, Christopher J. ;

Esteve, Jacques ;

Ogunbiyi, Olufemi J. ;

Azevedo e Silva, Gulnar ;

Chen, Wan-Qing ;

Eser, Sultan ;

Engholm, Gerda ;

Stiller, Charles A. ;

Monnereau, Alain ;

Woods, Ryan R. ;

Visser, Otto ;

Lim, Gek Hsiang ;

Aitken, Joanne ;

Weir, Hannah K. ;

Coleman, Michel P. .

LANCET, 2018, 391 (10125) :1023-1075

[5] Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer [J].

Altorki, Nasser ;

Lane, Maureen E. ;

Bauer, Thomas ;

Lee, Paul C. ;

Guarino, Michael J. ;

Pass, Harvey ;

Felip, Enriqueta ;

Peylan-Ramu, Nili ;

Gurpide, Alfonso ;

Grannis, Frederic W. ;

Mitchell, John D. ;

Tachdjian, Sabrina ;

Swann, R. Suzanne ;

Huff, Anne ;

Roychowdhury, Debasish F. ;

Reeves, Anthony ;

Ottesen, Lone H. ;

Yankelevitz, David F. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3131-3137

[6]

Alvarez Jean G Bustamante, 2019, Drugs Context, V8, P212566, DOI 10.7573/dic.212566

[7] LAG3 (CD223) as a cancer immunotherapy target [J].

Andrews, Lawrence P. ;

Marciscano, Ariel E. ;

Drake, Charles G. ;

Vignali, Dario A. A. .

IMMUNOLOGICAL REVIEWS, 2017, 276 (01) :80-96

[8] Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib [J].

Azuma, Koichi ;

Hirashima, Tomonori ;

Yamamoto, Nobuyuki ;

Okamoto, Isamu ;

Takahashi, Toshiaki ;

Nishio, Makoto ;

Hirata, Taizo ;

Kubota, Kaoru ;

Kasahara, Kazuo ;

Hida, Toyoaki ;

Yoshioka, Hiroshige ;

Nakanishi, Kaoru ;

Akinaga, Shiro ;

Nishio, Kazuto ;

Mitsudomi, Tetsuya ;

Nakagawa, Kazuhiko .

ESMO OPEN, 2016, 1 (04)

[9] Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer [J].

Bagley, Stephen J. ;

Kothari, Shawn ;

Aggarwal, Charu ;

Bauml, Joshua M. ;

Alley, Evan W. ;

Evans, Tracey L. ;

Kosteva, John A. ;

Ciunci, Christine A. ;

Gabriel, Peter E. ;

Thompson, Jeffrey C. ;

Stonehouse-Lee, Susan ;

Sherry, Victoria E. ;

Gilbert, Elizabeth ;

Eaby-Sandy, Beth ;

Mutale, Faith ;

DiLullo, Gloria ;

Cohen, Roger B. ;

Vachani, Anil ;

Langer, Corey J. .

LUNG CANCER, 2017, 106 :1-7

[10]

Bendell JC, 2020, CANCER RES, V80

← 1 2 3 4 5 6 7 8 9 10 →